文献速递瓣膜外科

年轻患者生物瓣主动脉瓣亚临床结构性瓣膜退变

Subclinical Structural Valve Degeneration in Young Patients With Bioprosthetic Aortic Valves.
PubMed 文献 · Ann Thorac Surg · 2021-03-19

本研究回顾性分析822例≤65岁行生物瓣主动脉瓣置换术患者,术后超声随访发现43.3%出现亚临床结构性瓣膜退变(SVD),其中仅21.5%进展为临床SVD或再次手术。亚临床SVD与长期生存无关,抗凝不影响其发生或进展。

要点

  • 年轻患者生物瓣SAVR后亚临床SVD发生率高(43.3%)。
  • 仅21.5%亚临床SVD进展为临床SVD或再手术。
  • 亚临床SVD未降低长期生存,抗凝无影响。

核心结论

  • 年轻患者生物瓣SAVR后亚临床SVD常见,但不影响生存或再手术率。

研究设计与样本

  • 单中心回顾性队列研究,纳入2002年1月至2018年6月≤65岁行生物瓣SAVR患者822例,排除感染性心内膜炎和院内死亡。

主要发现

  • 43.3%(356/822)患者出现亚临床SVD。
  • 亚临床SVD中仅21.5%进展为临床SVD或再次主动脉瓣手术。
  • 抗凝治疗未影响亚临床SVD的发生或进展。
  • 亚临床SVD有无与长期生存无差异。

关键数值与推荐

  • 亚临床SVD定义:与术后基线超声相比,平均跨瓣压差增加至少10 mm Hg和/或新发轻度瓣内反流或反流程度增加至少1级。

临床怎么用

  • 年轻患者生物瓣SAVR后应规律超声随访以识别亚临床SVD。
  • 亚临床SVD进展风险较低,无需过度干预。

局限性

  • 单中心回顾性研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bioprosthetic structural valve degeneration (SVD) has previously been a clinical diagnosis, but subclinical changes have been increasingly recognized in transcatheter valves. The significance of subclinical SVD after surgical aortic valve replacement (SAVR), however, is not well understood. The purpose of this study was to characterize the incidence and outcomes of subclinical SVD in young patients after SAVR. METHODS: Patients aged ≤65 years who underwent bioprosthetic SAVR between January 2002 and June 2018 at a single institution were included. Endocarditis cases and those with in-hospital mortality were excluded. All available longitudinal postoperative echocardiograms were reviewed. Subclinical SVD was defined as an increase in mean transvalvular gradient of at least 10 mm Hg and/or new onset of mild intraprosthetic regurgitation or increase by at least 1 grade, compared with baseline postoperative echocardiogram. RESULTS: Overall, 822 unique SAVR cases were included. Over the study period, 356 (43.3%) patients developed subclinical SVD. Only 21.5% of those with subclinical SVD progressed to clinical SVD or to repeat aortic valve procedures. In those with progression, the first signs of SVD occurred significantly earlier than in those whose changes remained stable (11 months vs 23 months; P = .036). Anticoagulation did not impact the development or progression of subclinical SVD. There was no difference in long-term survival for those who did or did not develop subclinical SVD. CONCLUSIONS: Subclinical SVD occurred in a large proportion of young patients undergoing bioprosthetic SAVR. Despite its high prevalence, subclinical SVD was not associated with decreased survival or repeat procedures.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Percy ED, Harloff M, Hirji S, et al. Subclinical Structural Valve Degeneration in Young Patients With Bioprosthetic Aortic Valves. Ann Thorac Surg. 2021. PMID: 32979371. doi:10.1016/j.athoracsur.2020.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。